NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
25.50
+0.04 (0.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
NAMS Revenue
NewAmsterdam Pharma Company had revenue of $29.11M in the quarter ending September 30, 2024, with 889.83% growth. This brings the company's revenue in the last twelve months to $33.59M, up 78.77% year-over-year. In the year 2023, NewAmsterdam Pharma Company had annual revenue of $14.09M, down -86.28%.
Revenue (ttm)
$33.59M
Revenue Growth
+78.77%
P/S Ratio
68.41
Revenue / Employee
$1,158,414
Employees
29
Market Cap
2.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
Dec 31, 2022 | 102.69M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNAMS News
- 8 days ago - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 10 days ago - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts - Seeking Alpha
- 10 days ago - Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
- 11 days ago - NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 11 days ago - Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - Benzinga
- 11 days ago - NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - GlobeNewsWire
- 15 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire